 <h1>Somatuline Depot Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>lanreotide</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about lanreotide. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Somatuline Depot.</p><h2>In Summary</h2><p><b>Common side effects of Somatuline Depot include:</b> diarrhea. <b>Other side effects include:</b> cholelithiasis, hypertension, and sinus bradycardia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to lanreotide: subcutaneous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, lanreotide (the active ingredient contained in Somatuline Depot) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking lanreotide:</p><p>
<i>More common</i>
</p><ul>
<li>Blurred vision</li>
<li>chest pain or discomfort</li>
<li>dizziness</li>
<li>gaseous abdominal or stomach pain</li>
<li>headache</li>
<li>lightheadedness, dizziness, or fainting</li>
<li>nervousness</li>
<li>pale skin</li>
<li>pounding in the ears</li>
<li>recurrent fever</li>
<li>slow, fast, or irregular heartbeat</li>
<li>stomach fullness</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bloating</li>
<li>chills</li>
<li>clay-colored stools</li>
<li>confusion</li>
<li>constipation</li>
<li>cough</li>
<li>dark urine</li>
<li>diarrhea</li>
<li>difficulty swallowing</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>fat in the stool</li>
<li>fever</li>
<li>hives, itching, skin rash</li>
<li>indigestion</li>
<li>large, hive-like swelling on face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals</li>
<li>loss of appetite</li>
<li>nausea</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>severe nausea or vomiting</li>
<li>stomach pain or cramps </li>
<li>sudden loss of weight</li>
<li>sweating</li>
<li>tightness in the chest</li>
<li>unusual drowsiness, dullness, or feeling of sluggishness</li>
<li>vomiting</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of lanreotide may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Difficulty having a bowel movement</li>
<li>difficulty with moving</li>
<li>excess air or gas in the stomach or bowels</li>
<li>feeling of fullness</li>
<li>inflammation, itching, lumps, or pain at the injection site</li>
<li>muscle pain or stiffness</li>
<li>pain in the joints</li>
<li>passing gas</li>
<li>weight loss</li>
</ul><p>
<!-- end subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to lanreotide: subcutaneous solution</i></p><h3>General</h3><p>The most common adverse events were gastrointestinal disorders, cholelithiasis, and injection site reactions.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 65%), abdominal pain (34%), vomiting (19%), flatulence (14%), nausea (11%), loose stools</p>
<p><b>Common</b> (1% to 10%): Constipation, flatulence, abdominal distension, abdominal discomfort, dyspepsia</p>
<p><b>Uncommon</b> (0.1% to 1%): Pancreatitis, feces discolored</p>
<p><b>Frequency not reported</b>: Steatorrhea<sup>[Ref]</sup></p><p>In one of the studies, diarrhea, abdominal pain, and flatulence increased as the dose increased.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Cholelithiasis (27%), bladder sludge (20%), new cholelithiasis </p>
<p><b>Common</b> (1% to 10%): ALT increased, AST abnormal, ALT abnormal, blood bilirubin increased, biliary dilatation </p>
<p><b>Uncommon</b> (0.1% to 1%): AST increased, blood alkaline phosphatase increased, blood bilirubin abnormal</p>
<p><b>Frequency not reported</b>: Cholecystitis</p>
<p><b>Postmarketing reports</b>: Steatorrhea, pancreatitis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Bradycardia (18%), hypertension (14%)</p>
<p><b>Common</b> (1% to 10%): Sinus bradycardia </p>
<p><b>Uncommon</b> (0.1% to 1%): Other cardiac adverse drug reactions<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Application site disorder (injection site mass/pain/reaction/inflammation/ nodule/pruritus, 30%)</p>
<p><b>Postmarketing reports</b>: Persisting induration, injection site abscess<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Dysglycemia (hypoglycemia, hyperglycemia, diabetes, 14%), weight decrease (11%)</p>
<p><b>Common</b> (1% to 10%): Blood glucose increased, glycosylated hemoglobin increased</p>
<p><b>Uncommon</b> (0.1% to 1%): Blood sodium decreased, diabetes mellitus aggravated<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (14%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Musculoskeletal pain (19%), arthralgia (11%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (16%)</p>
<p><b>Common</b> (1% to 10%): Dizziness</p>
<p><b>Postmarketing reports</b>: Dysautonomia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Dyspnea<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression</p>
<p><b>Uncommon</b> (0.1% to 1%): Insomnia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue</p>
<p><b>Uncommon</b> (0.1% to 1%): Hot flush, asthenia</p>
<p><b>Postmarketing reports</b>: Malaise<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Anti-lanreotide (the active ingredient contained in Somatuline Depot) antibodies<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Allergic reactions (including angioedema, anaphylaxis, and hypersensitivity)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Alopecia, hypotrichosis<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Rare</b> (less than 0.1%): Clinical hypothyroidism</p>
<p><b>Frequency not reported</b>: Slight decreases in thyroid function<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Somatuline Depot (lanreotide)." Ipsen Inc, Milford, MA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about Somatuline Depot (lanreotide)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>1 Review</li>
<li>Drug class: somatostatin and somatostatin analogs</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Somatuline Depot &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Carcinoid Syndrome</li>
<li>Neuroendocrine Carcinoma</li>
<li>Acromegaly</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to lanreotide: subcutaneous solution</i></p><h3>General</h3><p>The most common adverse events were gastrointestinal disorders, cholelithiasis, and injection site reactions.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 65%), abdominal pain (34%), vomiting (19%), flatulence (14%), nausea (11%), loose stools</p><p><b>Common</b> (1% to 10%): Constipation, flatulence, abdominal distension, abdominal discomfort, dyspepsia</p><p><b>Uncommon</b> (0.1% to 1%): Pancreatitis, feces discolored</p><p><b>Frequency not reported</b>: Steatorrhea<sup>[Ref]</sup></p><p>In one of the studies, diarrhea, abdominal pain, and flatulence increased as the dose increased.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Cholelithiasis (27%), bladder sludge (20%), new cholelithiasis </p><p><b>Common</b> (1% to 10%): ALT increased, AST abnormal, ALT abnormal, blood bilirubin increased, biliary dilatation </p><p><b>Uncommon</b> (0.1% to 1%): AST increased, blood alkaline phosphatase increased, blood bilirubin abnormal</p><p><b>Frequency not reported</b>: Cholecystitis</p><p><b>Postmarketing reports</b>: Steatorrhea, pancreatitis<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Bradycardia (18%), hypertension (14%)</p><p><b>Common</b> (1% to 10%): Sinus bradycardia </p><p><b>Uncommon</b> (0.1% to 1%): Other cardiac adverse drug reactions<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Application site disorder (injection site mass/pain/reaction/inflammation/ nodule/pruritus, 30%)</p><p><b>Postmarketing reports</b>: Persisting induration, injection site abscess<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Dysglycemia (hypoglycemia, hyperglycemia, diabetes, 14%), weight decrease (11%)</p><p><b>Common</b> (1% to 10%): Blood glucose increased, glycosylated hemoglobin increased</p><p><b>Uncommon</b> (0.1% to 1%): Blood sodium decreased, diabetes mellitus aggravated<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (14%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Musculoskeletal pain (19%), arthralgia (11%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (16%)</p><p><b>Common</b> (1% to 10%): Dizziness</p><p><b>Postmarketing reports</b>: Dysautonomia<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Dyspnea<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Depression</p><p><b>Uncommon</b> (0.1% to 1%): Insomnia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue</p><p><b>Uncommon</b> (0.1% to 1%): Hot flush, asthenia</p><p><b>Postmarketing reports</b>: Malaise<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Anti-lanreotide (the active ingredient contained in Somatuline Depot) antibodies<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Allergic reactions (including angioedema, anaphylaxis, and hypersensitivity)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Alopecia, hypotrichosis<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Rare</b> (less than 0.1%): Clinical hypothyroidism</p><p><b>Frequency not reported</b>: Slight decreases in thyroid function<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Somatuline Depot (lanreotide)." Ipsen Inc, Milford, MA. </p><h2>More about Somatuline Depot (lanreotide)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>1 Review</li>
<li>Drug class: somatostatin and somatostatin analogs</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Somatuline Depot &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Carcinoid Syndrome</li>
<li>Neuroendocrine Carcinoma</li>
<li>Acromegaly</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>